01 September 1997
Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - results of a randomized, placebo-controlled double-blind multicentre trial
Janos Feher, Istvan Lang, Arpad Gogl, Laszlo Varga, Laszlo Varga, Gabor Tompos, Laszlo PronaiMed Sci Monit 1997; 3(5): CR669-673 :: ID: 501567
Abstract
Eighty patients were included in a randomized, double-blind, placebo-controlled multicentre trial to determine the effect of L-ornithine-L-aspartate (Hepa-Merz¨) infusion on serum ammonia level in patients with liver cirrhosis accompanied by hyperammonaemia.Fourty patients received ornithine-aspartate (20 g in 250 ml 0,9% NaCl infusion solution administered intravenously during four hours) and 40 patients received placebo (250 ml 5% fructose solution). The follow-up time was seven days. Patients had alcoholic liver cirrhosis with hyperammonaemia (venous ammonia > 50 µmol/l). Patients treated with other hepatotherapeutic agents and those having alcohol withdrawal syndrome, consumption of alcohol during the study, gastrointestinal bleeding, pregnancy, severe concomitant diseases or fructose intolerance were excluded from the trial. Effect of treatment was evaluated by the clinical course and laboratory parameters of patients (venous ammonia level, g-GT, AST, ALT, AP, glucose, bilirubin, ChE, BUN, creatinine, albumin, prothrombin and hematological parameters) measured at 1, 3, 5 and 7 days of treatment.The seven-day ornithine-aspartate infusion therapy resulted in a significant decrease (p<0,05) of fasting ammonia concentration (-32%) when compared with that in the placebo group (-15%). There was no significant improvement in the routine laboratory parameters measured. Good tolerability and low rate of side effects were reported by the patients. In view of its demonstrated effect, ornithine-aspartate infusion can be considered as an effective therapy to decrease elevated serum ammonia level in cirrhotic patients.
Keywords: Liver Cirrhosis, ornithine-aspartate, hyperammonaemia
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952